Feng Wuwen, Liu Juan, Ao Hui, Yue Shijun, Peng Cheng
School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Theranostics. 2020 Sep 14;10(24):11278-11301. doi: 10.7150/thno.47289. eCollection 2020.
Intra- and interindividual variation in drug responses is one major reason for the failure of drug therapy, drug toxicity, and even the death of patients. Precision medicine, or personalized medicine, is a field of medicine that customizes an individual's medical diagnosis and treatment based on his/her genes, microbiomes, environments, etc. Over the past decade, a large number of studies have demonstrated that gut microbiota can modify the efficacy and toxicity of drugs, and the extent of the modification varies greatly from person to person because of the variability of the gut microbiota. Personalized manipulation of gut microbiota is an important approach to rectify the abnormal drug response. In this review, we aim to improve drug efficacy and reduce drug toxicity by combining precision medicine and gut microbiota. After describing the interactions between gut microbiota and xenobiotics, we discuss (1) the effects of gut microbiota on drug efficacy and toxicity and the corresponding mechanisms, (2) the variability of gut microbiota, which leads to variation in drug responses, (3) the biomarkers used for the patient stratification and treatment decisions before the use of drugs, and (4) the methods used for the personalized manipulation of gut microbiota to improve drug outcomes. Overall, we hope to improve the drug response by incorporating the knowledge of gut microbiota into clinical practice.
药物反应的个体内和个体间差异是药物治疗失败、药物毒性甚至患者死亡的一个主要原因。精准医学,即个性化医疗,是一个基于个体的基因、微生物群、环境等定制其医学诊断和治疗的医学领域。在过去十年中,大量研究表明肠道微生物群可改变药物的疗效和毒性,并且由于肠道微生物群的变异性,这种改变的程度在个体之间差异很大。对肠道微生物群进行个性化调控是纠正异常药物反应的重要方法。在本综述中,我们旨在通过结合精准医学和肠道微生物群来提高药物疗效并降低药物毒性。在描述了肠道微生物群与异生物素之间的相互作用后,我们讨论了:(1)肠道微生物群对药物疗效和毒性的影响及相应机制;(2)导致药物反应差异的肠道微生物群的变异性;(3)在用药前用于患者分层和治疗决策的生物标志物;(4)用于对肠道微生物群进行个性化调控以改善药物疗效的方法。总体而言,我们希望通过将肠道微生物群的知识纳入临床实践来改善药物反应。